Company Description
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide.
The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.
It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases.
The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
| Country | Germany |
| Founded | 1993 |
| IPO Date | Nov 4, 2021 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 5,061 |
| CEO | Christian Wojczewski |
Contact Details
Address: Essener Bogen 7 Hamburg, 22419 Germany | |
| Phone | 49 40 560 81 0 |
| Website | evotec.com |
Stock Details
| Ticker Symbol | EVO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| IPO Price | $26.16 |
| CIK Code | 0001412558 |
| CUSIP Number | 30050E105 |
| ISIN Number | US30050E1055 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Christian Wojczewski | Chief Executive Officer |
| Laetitia Rouxel | Chief Financial Officer and Member of Management Board |
| Dr. Cord Dohrmann Ph.D. | Chief Scientific Officer and Member of Management Board |
| Dr. Craig Johnstone Ph.D. | Chief Operating Officer and Member of Management Board |
| Aurelie Dalbiez | Chief People Officer and Member of Management Board |
| Volker Braun | Executive Vice President and Head of Global Investor Relations and ESG |
| Dr. Christian Dargel | Executive Vice President Global Head of Legal and Compliance |
| Gabriele Hansen | Senior Vice President and Head of Global Corporate Communications & Marketing |
| Dr. Ian M. Hunneyball | Senior Vice President of Programme Management and Clinical Operations |
| Dr. David Hallet | Executive Vice President |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 29, 2024 | 6-K | Report of foreign issuer |
| Nov 22, 2024 | 6-K | Report of foreign issuer |
| Nov 15, 2024 | 6-K | Report of foreign issuer |
| Nov 8, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Nov 6, 2024 | 6-K | Report of foreign issuer |
| Aug 14, 2024 | 6-K | Report of foreign issuer |
| Aug 14, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Aug 6, 2024 | 6-K | Report of foreign issuer |
| Jun 10, 2024 | 6-K | Report of foreign issuer |
| May 22, 2024 | 6-K | Report of foreign issuer |